Antibody

26개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved26 programs
AntibodyLimited DatastaleRoche Pharma AGPhase 2

Dinutuximab beta (Dinutuximab beta)

Neuroblastoma · Relapsed Neuroblastoma

#RelapsedNeuroblastoma#Antibody#Phase2#monoclonal-antibody#Neuroblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Ivonescimab Combined With Chemotherapy (Ivonescimab Combined With Chemotherapy)

Relapsed or Metastatic Thymic Cancer; First-line Treatment · Relapsed or Metastatic Thymic Cancer

#RelapsedorMetastaticThymicCancer#Antibody#Phase2#monoclonal-antibody#First-lineTreatment+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#FollicularLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →